-
Document de presse | 2021.09.27
SARS-CoV-2: different immune responses observed in nasal mucosa and blood
The clinical manifestations of SARS-CoV-2 infection vary from one individual to the next, and much remains unknown about the mechanisms underpinning this variability. Since the nasal mucosa is one of the first entry points of the virus, scientists from the Institut Pasteur and Inserm, in collaboration with Cochin AP-HP Hospital, analyzed in parallel the immune responses in the nasal mucosa and in...
-
News | 2021.09.30
DIM ELICIT Symposium on Wednesday, October 20, 2021 at IPGG: registrations are open!
The DIM ELICIT (Empowering LIfe sCiences with Innovative Technologies) is organizing its closing event on Wednesday, October 20, 2021 at the Pierre-Gilles-de-Gennes Institute for Microfluidics (IPGG). The program will highlight the most emblematic projects of the DIM ELICIT with interventions in the form of pairs (biologist/technologist). This will be also an opportunity to exchange with the...
-
News | 2021.10.15
The Institut Pasteur de Guinée: a young institute in the midst of the COVID-19 crisis
The decision to set up an Institut Pasteur in Guinea was made in 2014 in response to the Ebola crisis. It reflects the joint determination of France and Guinea to tackle emerging outbreaks on a long-term basis for the welfare of the population. When the COVID-19 pandemic struck, how was this young institute able to fulfill its remit as a front-line laboratory?When the first case of COVID-19 was...
-
Document de presse | 2021.10.26
The intranasal lentiviral vaccine candidate (Lenti-S) protects brain and lung in a pre-clinical animal model
The SARS-CoV-2 virus, responsible for the COVID-19 pandemic, primarily targets the respiratory tract, but its ability to infect cells of the nervous system has also been largely reported. Indeed, the expression of the receptor of this virus, the Angiotensin Converting Enzyme 2 (ACE2), by neuronal and glial cells makes the brain susceptible to SARS-CoV-2. Moreover, neurological manifestations are...
-
Document de presse | 2022.02.16
SARS-CoV-2-related viruses capable of infecting human cells discovered in bats in northern Laos
Since the emergence of SARS-CoV-2, several animal species have been studied to identify potential reservoirs and/or intermediate hosts of the virus. Scientists from the Institut Pasteur du Laos and the National University of Laos recently set out to shed light on the evolution of SARS-CoV-2 and explore the potential presence of SARS-CoV-2-related coronaviruses in the natural environment by...
-
Article | 2022.03.29
PPU-Research & Technology Program
The PPU-Research & Technology Program gives access to a stimulating technological environment to carry out PhD student’s research project. This includes opportunities to conduct technological and methodological co-developments on high-end equipment under the supervision/in partnership with technology platforms or service and research units (UTechS). In addition, students of the PPU-Research...
-
Article | 2022.05.30
Afroscreen Project : boosting variant surveillance in 13 african countries
The Agence française de développement (AFD) and ANRS | Maladies infectieuses émergentes, in partnership with the Institut Pasteur, IRD, and laboratories across 13 African countries, are launching the joint AFROSCREEN project. This project meets an urgent need for surveillance of the development of SARS-CoV-2 variants and other emerging pathogens by bolstering laboratory genomic sequencing...
-
Document de presse | 2022.06.29
Rethinking the rabies vaccine
Rabies virus kills over 50,000 people each year. Although current rabies vaccines are effective, they do not offer lifelong protection and booster doses are required. Institut Pasteur scientists, in collaboration with researchers from La Jolla Institute for Immunology (LJI) in the United States, captured new high-resolution views of rabies virus, revealing potential vaccine targets. These...
-
News | 2022.07.01
Monitoring and early warning: Pasteur Center in Cameroon plays an active role in the response to SARS-CoV-2 virus
As a first-line laboratory in the event of a health emergency, the Pasteur Center in Cameroon was naturally designated as a COVID-19 reference laboratory by the Cameroon health authorities in 2020. How did the Pasteur Center in Cameroon organize its response to this emerging novel virus at national level throughout the epidemic, and how is it monitoring the virus today?At the beginning of the...
-
News | 2022.07.09
Conversation: capacity building to prepare for the future
Institut Pasteur Senior Executive Scientific Vice-President Christophe d'Enfert provides a brief, cross-disciplinary overview of 2021 covering capacity building, enhanced partnerships and future technologies.